Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baram, D.
Right arrow Articles by Richman, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baram, D.
Right arrow Articles by Richman, P. S.
(Chest. 2005;128:869-875.)
© 2005 American College of Chest Physicians

Impact of Rapid On-Site Cytologic Evaluation During Transbronchial Needle Aspiration*

Daniel Baram, MD; Ruel B. Garcia, MD and Paul S. Richman, MD

* From the Division of Pulmonary/Critical Care, Stony Brook University, Stony Brook, NY.

Correspondence to: Daniel Baram, MD, Assistant Professor of Medicine, Stony Brook University, Division of Pulmonary/Critical Care, T-17, 040 HSC, Stony Brook NY 11794-8172; e-mail: dbaram{at}notes.cc.sunysb.edu

Study objective: To determine the extent to which rapid on-site cytologic evaluation (ROSE) of transbronchial needle aspiration (TBNA) samples can safely and cost-effectively reduce the need for additional biopsy during bronchoscopy.

Setting: University Hospital in Long Island, NY.

Patient and methods: Forty-four bronchoscopies with TBNA, most of which utilized ROSE, were evaluated prospectively. The number and types of biopsies performed during each procedure were compared to a preprocedural algorithm to determine the impact of knowing ROSE results during the procedure. Bronchoscopies performed with and without ROSE were compared, as were bronchoscopies with diagnostic and nondiagnostic ROSE results. A cost analysis was performed comparing the Medicare reimbursement for ROSE to the savings of deferring multiple biopsies.

Results: Thirty-two bronchoscopies were performed with ROSE; 12 were performed without ROSE. Fewer biopsies were performed during bronchoscopies utilizing ROSE. Diagnostic yield, TBNA sensitivity and accuracy, and procedural time were similar between these two groups.

Conclusions: ROSE during TBNA allows for deferring additional biopsy without loss in diagnostic yield, likely lowers procedural risk, and is cost-effective.

Key Words: bronchoscopy • cancer diagnosis • transbronchial needle aspiration




This article has been cited by other articles:


Home page
 ChestHome page
H. S. Lee, G. K. Lee, H.-S. Lee, M. S. Kim, J. M. Lee, H. Y. Kim, B.-H. Nam, J. I. Zo, and B. Hwangbo
Real-time Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Mediastinal Staging of Non-Small Cell Lung Cancer: How Many Aspirations Per Target Lymph Node Station?
Chest, August 1, 2008; 134(2): 368 - 374.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.